Company profile
PharmaCielo Ltd.
OTC: PCLOF · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Toronto, ONReports USD
#813 of 1,422 Healthcare companies by revenue26th-percentile growth
EA Score
40DFH 42DQ —GM 29SS 53
v0.1 · 45/100 weight · provisional
↑ Piotroski F, workforce scale · ↓ balance-sheet leverage, 3-yr revenue growth
Methodology →Revenue TTM
$2.6M
Rev growth YoY (TTM)
+1.9%
Net income (FY)
-$2.8M
Employees
268
as of 2026-08-22
Market cap
$9.6M
as of 2026-08-22
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.9M2.6M CAD2025
Net income-$2.8M-4.0M CAD2025
Operating income-$2.8M-3.8M CAD2025
Total assets$6.2M8.6M CAD2025
Liabilities$17.4M23.9M CAD2025
Equity-$11.2M-15.3M CAD2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is PharmaCielo Ltd.’s revenue?
PharmaCielo Ltd. booked $1.9M in FY2025 revenue, contracting 27% year over year — slower than 74% of Healthcare companies we track, at a -153.0% net margin.
Peers · Healthcare
Bio Essence Corporation52DResonate Blends, Inc.——Vycor Medical, Inc.56CWest Island Brands Inc.——BioRegenx, Inc.30DInnovative MedTech Inc.49DKey facts
CEOMarc Lustig
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersToronto, ON
ExchangeOTC: PCLOF
Employees268
IPO date2019-01-25
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.